| Literature DB >> 29847566 |
MaFeng Liu1,2,3, Mi Huang1,2,3, Yun Shui1,2,3, Francis Biville4, DeKang Zhu2,3, MingShu Wang1,2,3, RenYong Jia1,2,3, Shun Chen1,2,3, KunFeng Sun1,2,3, XinXin Zhao1,2,3, Qiao Yang1,2,3, Ying Wu1,2,3, XiaoYue Chen2,3, AnChun Cheng1,2,3.
Abstract
Iron is one of the most important elements for bacterial survival and pathogenicity. The iron uptake mechanism of Riemerella anatipestifer (R. anatipestifer, RA), a major pathogen that causes septicemia and polyserositis in ducks, is largely unknown. Here, the functions of the putative TonB-dependent iron transporter of RA-CH-1, B739_1343, in iron utilization and pathogenicity were investigated. Under iron-starved conditions, the mutant strain RA-CH-1ΔB739_1343 exhibited more seriously impaired growth than the wild-type strain RA-CH-1, and the expression of B739_1343 in the mutant strain restored growth. qRT-PCR results showed that the transcription of B739_1343 was not regulated by iron conditions. In an animal model, the median lethal dose (LD50) of the mutant strain RA-CH-1ΔB739_1343 increased more than 104-fold (1.6×1012 CFU) compared to that of the wild-type strain RA-CH-1 (1.43×108 CFU). In a duck co-infection model, the mutant strain RA-CH-1ΔB739_1343 was outcompeted by the wild-type RA-CH-1 in the blood, liver and brain of infected ducks, indicating that B739_1343 is a virulence factor of RA-CH-1. Finally, immunization with live bacteria of the mutant strain RA-CH-1ΔB739_1343 protected 83.33% of ducks against a high-dose (100-fold LD50) challenge with the wild-type strain RA-CH-1, suggesting that the mutant strain RA-CH-1ΔB739_1343 could be further developed as a potential live attenuated vaccine candidate for the duck industry.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29847566 PMCID: PMC5976166 DOI: 10.1371/journal.pone.0197310
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Growth curves for RA-CH-1pLMF03, RA-CH-1ΔB739_1343pLMF03, and RA-CH-1ΔB739_1343pLMF03::B739_1343 in TSB, TSB supplemented with 120 μM Dip and TSB supplemented with 120 μM Dip and 300 μM iron (III) chloride.
Cells were grown in 20 mL of TSB medium or TSB medium supplemented with Dip or TSB medium supplemented with Dip and iron (III) chloride at 37°C, starting at OD600 = 0.1. OD600 values were measured every 2 h for 14 h. Data were analyzed using two-way ANOVA. The error bars represent the standard deviations of three independent experiments and two replicate samples for each experiment (n = 3).
Fig 2Growth of RA-CH-1pLMF03, RA-CH-1ΔB739_1343pLMF03, and RA-CH-1ΔB739_1343pLMF03::B739_1343 on TSA and TSA supplemented with 50 μM Dip.
The R. anatipestifer strains (clockwise from top left) RA-CH-1pLMF03, RA-CH-1ΔB739_1343pLMF03, and RA-CH-1ΔB739_1343pLMF03::B739-1343 were grown on TSA plates containing cefoxitin (1 μg/mL) and 0 μM Dip (A) or 50 μM Dip (B). Growth was assessed by the appearance of bacterial colonies on plates. Pictures were taken after 48 h of growth at 37°C. All the experiments were repeated three times. Representative plates are presented.
Fig 3Competition assay of wild-type RA-CH-1 (filled symbols) and the mutant strain RA-CH-1ΔB739_1343 (open symbols) in vivo.
The wild-type strain RA-CH-1 (109 CFU) and RA-CH-1 ΔB739_1343 (109 CFU) were mixed at a 1:1 ratio and injected into the leg muscles of 3-day-old ducklings. At 24 h (A) and 48 h (B) post-infection, bacteria were isolated from the livers, brains and blood according to the method described in the “Materials and Methods” section. The data points represent the CFU/g of individual animals in the indicated organs; the bars show the median values (n = 6).
Duck body weight before challenge and body weight gain (mean±SD).
| Group | Immunization | Body weight before vaccination (g) | Body weight gain after vaccination (g) | |||
|---|---|---|---|---|---|---|
| D3 | D6 | D9 | D12 | |||
| 1 | PBS | 86.25±7.02 | 66.1±5.38 | 141.1±11.48 | 245.4±19.97 | 331.9±27.01 |
| 2 | RA-CH-1 | 85.65±7.6 | 66.85±5.94 | 143.8±12.77 | 229.5±20.37 | 337.1±29.93 |
| 3 | Inactivated RA-CH-1 vaccine | 85.5±7.54 | 61.1±5.39 | 141±12.44 | 229.9±20.28 | 326.1±28.77 |
| 4 | - | 85.7±6.67 | 58.2±4.53 | 134.8±10.48 | 226.6±17.62 | 353.2±27.47 |
aNumber of ducks in a group (n = 20).
Fig 4Serum antibody titers of ducks vaccinated with RA-CH-1ΔB739_1343 and the inactivated RA-CH-1 vaccine (n = 5).
Serum was collected from the ducks at 7-day intervals from day 7 to day 49 post-vaccination, and serum antibodies against RA-CH-1 were quantified using indirect ELISA. The antibody titers represent the highest dilutions that produced positive results. The data represent the average value from five serum samples for each group. The statistical significance of the data was ascertained with Student’s T test. This experiment was performed using three independent experiments and three replicate samples in each experiment (n = 3).
Animal challenge experiment.
| Group | Immunization | Challenge strain | No. of deaths (total) | No. showing morbidity (total) | Mortality (%) | Morbidity (%) | Protection |
|---|---|---|---|---|---|---|---|
| 1 | PBS | RA-CH-1 | 15(20) | 18(20) | 75% | 90% | - |
| 2 | RA-CH-1 | RA-CH-1 | 3(20) | 3(20) | 15% | 15% | 83.33% |
| 3 | Inactivated RA-CH-1 vaccine | RA-CH-1 | 0(20) | 0(20) | 0 | 0 | 100% |
| 4 | - | - | 0(20) | 0(20) | 0 | 0 | - |
aThe challenge strain dose was 100 LD50.
bThe protection rate was calculated as [1−(% Morbidity in vaccinate/% Morbidity in control)]×100
Strains and plasmids used in this study.
| Strains and plasmids | Genotype or serotype | Source or reference |
|---|---|---|
| XL1-BLUE | F- supE44 hdsR17 recA1 endA1 gyrA46 thi relA1 lac- F’ proAB- lacIq lacZΔM15 Tn10, Tetr | Laboratory collection |
| S17-1 | Thi-1 thr leu tonA lac Y supE recA::RP4-2-Tc::Mu Kanr | [ |
| S17-1 pEX18GM:: | S17-1 carrying pEX18GM:: | This study |
| RA-CH-1 | Laboratory collection | |
| RA-CH-1 | This study | |
| RA-CH-1 | This study | |
| pEX18GM | oriT+, sacB+, gene replacement vector with MCS from pUC18, Genr | [ |
| pAM238 | pSC101 origin, Spcr | [ |
| pEX18GM:: | pEX18GM carrying | This study |
| pLMF03 | [ | |
| pLMF03:: | pLMF03 carrying | This study |
Ampr, ampicillin resistance; Genr, gentamicin resistance; Kanr, kanamycin resistance; Spcr, spectinomycin resistance; Cfxr, cefoxitin resistance.